• Patients volunteered to participate in this study and signed informed consent;

• Age 18-75, male or female;

• ECOG PS score 0-2;

• Child-pugh liver function grading: Grade A or B

• The clinical diagnosis conforms to primary hepatocellular carcinoma (HCC) and the lesion conforms to stage III according to China liver cancer staging (CNLC)

• Did not received any type of other first-line drugs such as Sorafenib

• According to RECIST 1.1 standard, patients have at least one measurable lesion (CT/MRI scan long diameter ≥10mm or CT/MRI scan short diameter ≥15mm for lymph node lesions, and the lesion has not received radiotherapy, freezing or other local treatments);

• Expected survival ≥ 12 weeks;

• The function of vital organs meets the following requirements (excluding the use of any blood component and cell growth factor within 14 days) :

• Blood routine:

• White blood cells count ≥3.0×109/L Platelet count ≥70×109/L Hemoglobin ≥80g/L;

• Liver and kidney function:

• Serum creatinine (SCr) ≤ 1.5 times upper limit of normal value (ULN) or creatinine clearance ≥50 ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN); AST or ALT levels ≤ 3 times the upper limit of normal value (ULN)

⁃ Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during and within six months of the end of medication;Patients with negative serum or urine pregnancy tests within 7 days prior to study inclusion and who must be non-lactating, and males should agree to use contraceptives during the study period and for 6 months after the end of the study period.

⁃ Subjects have good compliance and cooperate with the follow-up.

⁃ Subjects with HBV or HCV infection should receive anti-virus treatment without interfron.